Celldex Therapeutics, Inc.
CLDX· Nasdaq
Released Nov 6, 2024, after the close
10-Q filed Nov 6, 2024, 37 days after period end · 0001410578-24-001766
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $3.19M | $1.52M | $407.00K | $153.00K |
| Net Income | -$42.12M | — | — | — |
| EPS Diluted |
Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR
| -$0.64 |
| -$0.81 |
| -$0.57 |
| -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.